Sonoma Pharmaceuticals (SNOA) has completed transition to the new European Union Medical Device Regulation for four of its products in Europe. Sonoma was granted classification as a Class IIb medical device for Microdacyn60 Wound Care and Microdacyn60 Hydrogel, its scar gel product Epicyn, and Pediacyn for atopic dermatitis. The MDR was adopted in the EU in 2017 to replace the existing Medical Device Directive. The transition period for compliance was most recently extended to December 31, 2028 for non-implantable Class IIb and lower risk devices. In order to comply with the MDR, Sonoma’s products needed to meet certain requirements relating to safety and performance and successfully undergo verification of regulatory compliance, or conformity assessment.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNOA:
- Sonoma Pharmaceuticals Ends EMC Pharma Agreement
- Sonoma Pharmaceuticals announces relaunch of dermatology, eye care lines
- FDA grants Sonoma 510(k) approval for Microdacyn Hydrogel
- Sonoma Pharmaceuticals reports Q2 (59c) vs ($5.75) last year
- Sonoma Pharmaceuticals expands partnership with healthcare distributor
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
